Pipeline overview

Evexta Bio is a biopharmaceutical company exploring the new frontiers of oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications:

Rupitasertib

Unique dual S6K AKT1/3 inhibitor
In-licensed from Merck KGaA

ER+ HER2- Breast Cancer

| Combination with SERD
Discovery
Preclinical
Phase 1
Phase 2

ER+ HER2- Breast Cancer

| Combination with CDK4/6i
Discovery
Preclinical
Phase 1
Phase 2

HER2+ Breast Cancer

| Combination with trastuzumab
Discovery
Preclinical
Phase 1
Phase 2

Glioblastoma multiforme

| Combination with radiotherapy
Discovery
Preclinical
Phase 1
Phase 2

Gastric Cancer

| Combination with SOC
Discovery
Preclinical
Phase 1
Phase 2

EVX-020

Sole-in-class KIF20A Inhibitor
Proprietary program

Hematologic Malignancies

| Payload for ADC
Discovery
Preclinical
Phase 1
Phase 2

Solid Tumors

| Payload for ADC
Discovery
Preclinical
Phase 1
Phase 2